by Stephen Levin
While there is no single recipe for building a successful medical device company, the current proliferation of venture-backed start-ups may...
Invatec: From Garage to Global Cardiology Brand
Staying close to the customer has become a cliche--one that most companies begin by adhering to, but which becomes more difficult to maintain as a company grows. Invatec started as a family-run business centered around turning physicians' ideas into new products. The success of Invatec's initial products led to the company's transformation into one selling both cardiology devices and innovative products in the carotid and peripheral markets. Invatec started by building a growing global business outside of the US, and it is seeing early success from its initial US product introductions, where it is challenging the major cardiology companies on their home turf.
More from Business Strategy
• By
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
• By
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
• By
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
More from In Vivo
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
• By
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
• By
Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.